¹Department of Biological Sciences, University of Notre Dame, Notre Dame, IN 46556, USA

Correspondence: M Tenniswood, Department of Biological Sciences, University of Notre Dame, Notre Dame, IN 46556, USA. Tel: +1-574-631-3372; Fax: +1-574-631-7413; E-mail: Tenniswood.1@nd.edu

Received 12 May 2004; Revised 17 December 2004; Accepted 17 December 2004; Published online 4 March 2005.

Abstract

In LNCaP prostate cancer cells CG-1521, a new inhibitor of histone deacetylases, alters the acetylation of p53 in a site-specific manner. While p53 is constitutively acetylated at Lys320 in LNCaP cells, treatment with CG-1521, stabilizes the acetylation of p53 at Lys373, elevating p21 (and inducing cell cycle arrest). Treatment with CG-1521 also promotes Bax translocation to the mitochondria and cleavage, and apoptosis. TSA stabilizes the acetylation of p53 at Lys382, elevating p21 levels and inducing cell cycle arrest, but does not induce Bax translocation or apoptosis. In LNCaP cells CG-1521, but not TSA, promotes the rapid degradation of HDAC2. These data suggest that the acetylation of p53 at Lys373 is required for the p53-mediated induction of cell cycle arrest and apoptosis, while acetylation of p53 at Lys382 induces only cell cycle arrest. In p53^-/- PC3 cells both compounds induce p21 and cell cycle arrest, but not Bax translocation or apoptosis, suggesting that both compounds can also induce p21 through a p53-independent mechanism.